摘要
目的观察罗格列酮对肥胖型2型糖尿病患者颈动脉硬化的影响。方法将128例肥胖型2型糖尿病患者随机分为治疗组和对照组。治疗组在原治疗基础上给予罗格列酮4mg/d。治疗前和治疗6个月检查空腹血糖(FBG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)和血脂水平。计算胰岛素抵抗指数(IRI)和胰岛素敏感指数(ISI)。用彩色多普勒超声检查颈动脉内中膜厚度(IMT)、管腔内径、斑块的数量和类型。结果治疗组FBG、FINS、甘油三酯、HbA1c均明显降低(P<0.05),ISI显著上升(P<0.01);IRI显著下降(P<0.01)。治疗后颈动脉IMT减少、管腔内径增大、斑块的数量减少和类型改变与治疗前和对照组比较差异有统计学意义(P<0.05)。结论罗格列酮治疗肥胖型2型糖尿病患者在降低血糖、改善IRI、提高ISI的同时,并在一定程度上延缓其颈动脉硬化斑块的发生和稳定斑块。
Objective To observe the effect of rosiglitazone on carotid atherosclerosis in patients with type 2 diabetes mellitus（T2DM） and obesity. Methods In this study 128 cases of T2DM with obesi- ty were randomly divided into treatment group and control group. The control group received routine therapy alone. The treatment group were treated with rosiglitazone 4mg/d on the basis routine therapy for six months. Fasting blood glucose （ FBG）, fasting insulin （ FINS）, hemoglobin A1c （HbA1c） and lipid level were checked before and after six months. Calculated the insulin resistance index （IRI） and insulin sensitive index（ISI）. The numbers and types of their carotid atheromatous plaques, carotid inner diameters,ca-rotid intima-media thickness（IMT） were measured with Doppler uhrasonography. Results After Rosiglitazone treatment for six months, blood glucose,insulin,HbA1 c and triglyceride decreased significantly（P〈0.05）, IRI decreased （P〈0.01） and ISI increased （ P 〈 0.01 ）. At the same time, the decrease of plagues, numbers,the changes of plagues, type and the dinilution of IMT all have statistical significance （P 〈 0.05）. Conclusion Rosiglitazone can decrease blood glucose, insulin and insulin resistance index and increase insulin sensitive index. To some extent,it can retard atherosclerosis progression and stable arterial plague in patients with T2DM and obesity.
出处
《临床内科杂志》
CAS
2008年第10期696-698,共3页
Journal of Clinical Internal Medicine
关键词
罗格列酮
2型糖尿病
肥胖
颈动脉硬化
Rosiglitazone
Type 2 diabetes mellitus
Obesity
Carotid atherosclerosis
